Phase III SWOG S1203: Idarubicin + High-Dose Cytarabine ± Vorinostat vs Standard Therapy in Newly Diagnosed AML

Slideset - In this phase III trial, idarubicin plus high-dose cytarabine with or without vorinostat did not show superiority to 7 + 3 regimen in untreated AML patients 60 years of age or younger.

Source: Clinical Care Options Leukemia - December 8, 2016 Category: Hematology Source Type: research